News & Media
Press Releases
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases
June 2, 2020
Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and …
Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate
July 31, 2019
Amolyt Pharma 3 announces that it has completed a €67 million Series A financing round …
Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases
November 14, 2018
Announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading global rare disease company …
Presentations
- All PRESENTATIONS
- AZP-3813
- AZP-3601
- AZP-3404
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- AZP-3601
- AZP-3404
AZP-3601
Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism
Written by
Dan Hennings
AZP-3601
Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States
Written by
walid
Upcoming events
Hypopara Awareness Day
Date: June 1, 2022
ENDO 2022 – Annual Meeting of the Endocrine Society
Date: June 10 – June 14, 2022 (Atlanta, Georgia)
ASBMR 2022 Annual Meeting
Date: September 9 - 12, 2022 (Austin, TX)
Social Updates
TWITTER
We are pleased to announce the addition of Mark Sumeray, M.D. to our team as #CMO. Dr. Sumeray bring...
Read More »We're looking forward to joining other leaders in the #endocrine space at #ENDO2022. Our oral presen...
Read More »Our #CEO, Dr. Thierry Abribat, was featured in a recent @Pharmashot interview discussing the investi...
Read More »